Lincoln Pharmaceuticals Ltd

AGM Details

• Date and start time: 30 September 2026, 11:00 AM.
• Mode: meeting conducted through video conferencing.
• Attendance: 80 shareholders attended via VC.
• Chair: Mahendra G. Patel presided; Kishor Shah absent.
• Annual report and related documents circulated electronically on 5 September 2026.
• Documents available for electronic inspection during the meeting.

Key Resolutions

• Adopt standalone and consolidated financial statements for year ended 31 March 2026.
• Dividend declaration: Rs 1.80 per equity share.
• Re-appointment of Hashmukh I. Patel as Director.
• Re-appointment of Munjal Mahendrabhai Patel as Director.

Special / Other Resolutions

• Ratification of remuneration payable to Kiran J. Mehta & Co. for FY ending 31 March 2027.

Governance & Scrutiny

• Chairperson Seema Mehta chairs Audit, Nomination & Remuneration, and Stakeholders committees.
• Scrutinizer appointed: Umesh Parikh for e-voting; results to be declared within two working days.
• Directors retiring by rotation were recommended for re-appointment: Hashmukh Patel and Munjal Patel.

Lincoln Pharmaceuticals Ltd: Trading Window closed from October 01, 2026 till 48 hours after the declaration of the Financial Results for the quarter ended September 30, 2026.

Dividend/AGM details

• Security: Equity shares of Rs 10 each.
• Record Date: 11 September 2026.
• Book Closure: 12 September 2026 to 30 September 2026.
• Dividend: 18% final; ₹1.80 per equity share.
• Dividend FY: 2025-26 (April 1, 2025–March 31, 2026).
• AGM date: 30 September 2026.
• Payable only if approved by members at the AGM.
• Purpose: entitlement for dividend if approved.

Book Closure Details

• Book closure starts September 12, 2026 and ends September 30, 2026.
• Security affected: Equity shares of Rs 10 each.
• Purpose: determine entitlement for dividend if approved at AGM.
• AGM date: September 30, 2026.
• Dividend declared: final dividend ₹1.80 per share.
• Dividend rate: 18% for the year 2025-26.
• Dividend payable only if approved by members at AGM.
• Dividend for FY 2025-26: Apr 01, 2025 to Mar 31, 2026.

Board decisions and financial disclosures

• Board approved unaudited standalone and consolidated Q1 FY27 results for quarter ended 30 June 2026.
• Extracts of unaudited consolidated results to be published; full results on LincolnPharma.com.
• Standalone Q1 FY27 revenue Rs 17,728.21 Lakh; net profit Rs 3,623.45 Lakh.
• Consolidated Q1 FY27 net profit Rs 3,623.45 Lakh.
• Consolidated results include subsidiary Zullinc Healthcare LLP.
• Limited review conducted; auditor did not express an audit opinion.
• Dividend recommended: 18% (Rs 1.80 per share) for FY25-26, subject to AGM.

Meeting Details

• Board meeting on 13 August 2026 at the Company's Registered Office.

Key Agenda Items

• Consider and approve unaudited standalone and consolidated financial results for quarter ended 30 June 2026.
• Any other business with the permission of the Chairman, if any.

Other Notes

• Trading window closed from 01 July 2026; will reopen after 48 hours of results generally available.

Dematerialisation & listing confirmation

• Dematerialisation requests processed during the quarter were confirmed to the depositories.
• Dematerialised securities have been listed on the exchanges where the prior securities are listed.
• Physical certificates received for dematerialisation were mutilated and cancelled; depository name registered as owner within prescribed timelines.